DCGI asked to stop over-the-counter sale of nicotine gums by the Delhi government

  • News
  • December 24, 2017

The Delhi government’s health department sent written request to the Drug Controller General of India (DGCI) to stop the over-the-counter sale of nicotine gums and lozenges without an authorized prescription. Dr. SK Arora in a letter addressing Dr. GN Singh, additional director (Health) said nicotine have potential addiction property and people can use like a drug in the form of gums and lozenges which were being sold at medical shops over the counter without any prescription.

During counseling, motivation and behavioral therapy, People addicted to a small percentage of moderate tobacco users may require these drugs as nicotine replacement therapy (NRT) under the supervision of qualified counsellors. But the selling of these drugs over the counter without any prescription promotes malpractices and self-therapy, it may lead to merely shifting the person from one addiction to another, the letter read.

Dr. Arora said the youngsters who can’t use tobacco products directly due to social or family fear may easily use them, s they should stop selling over counters.

  • Related Posts

    • News
    • February 1, 2025
    • 239 views
    Union Budget 2025 pleased Healthcare Leaders except for a Letdown or two

    New Delhi: Healthcare leaders expressed overall satisfaction over Union Budget 2025 except for a letdown or two. Rajiv Nath, Forum Coordinator, Association of Indian Medical Device Industry (AiMeD), though appreciated…

    ‘A Knight in Shining Armor’ packed a punch in FOGSI for Gender Equality

    New Delhi: There was no fog in sight; FOGSI was shining as never before, thanks to the leadership of its outgoing president Dr Hrishikesh Pai. The over 40, 000 strong…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Aurobindo Pharma shares jump 4% as arm completes phase1 trial for bone drug

    Aurobindo Pharma shares jump 4% as arm completes phase1 trial for bone drug

    ‘Pharma companies need to look beyond US market’

    ‘Pharma companies need to look beyond US market’

    HC upholds validity of Bihar pharmacist rules

    HC upholds validity of Bihar pharmacist rules

    CAHOCON 2025 marks Highest Point in Quest for Culture of Patient Safety

    CAHOCON 2025 marks Highest Point in Quest for Culture of Patient Safety